Taking people in Olaszország1/2. fázis
A long-term monitoring study of patients suffering from a malignant neoplasm of the central nervous system previously treated with hematopoietic stem cells
Key facts
- Where
- Milan, OlaszországSee the 2 sites
- Phase
- 1/2. fázis
Where in Olaszország
- IRCCS Foundation Istituto Neurologico Carlo BestaMilan, OlaszországTaking people
- Ospedale San Raffaele S.r.l.Milan, OlaszországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Genenta Science S.p.A.
- Trial code
- EU 2024-516211-25-00
- Record updated
- 2024. augusztus 26.
- Original description
The primary objective is to evaluate the long term mutagenic safety of Temferon.Read full original descriptionShow less
A follow-up study evaluating the long term safety of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-α2 gene previously administered to patients with glioblastoma multiforme
The primary objective is to evaluate the long term mutagenic safety of Temferon.
Inclusion: Patients who have received Temferon and completed the follow-up in the TEM-GBM_001 study; Able and willing to provide written informed consent and comply with the study protocol and procedures.
Exclusion: There are no exclusion criteria for this study.